Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2017 Summary According to the recently published report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Hematological Disorders, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Non-Small Cell Lung Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Angina (Angina Pectoris), Arteriosclerosis, Chronic Heart Failure, Colorectal Cancer, Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Myocardial Ischemia, Parkinson's Disease, Rheumatoid Arthritis, Solid Tumor and Thromboangiitis obliterans (Buerger disease). Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects - The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview 7 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 13 Products under Development by Universities/Institutes 17 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment 19 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development 25 AnGes MG Inc 25 F-star Biotechnology Ltd 25 Kringle Pharma Inc 26 M3 Biotechnology Inc 26 Minerva Biotechnologies Corp 26 Molecular Partners AG 27 ViroMed Co Ltd 27 Yooyoung Pharm Co Ltd 28 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles 30 beperminogene perplasmid - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 FS-101 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Gene Therapy to Activate HGF for Myocardial Infarction - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MM-201 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MP-0250 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 NDX-1017 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 NK-4 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 SL-186 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 SL-188 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 VM-202 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 YYB-101 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products 51 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products 53 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones 54 Featured News & Press Releases 54 Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers 54 Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials 55 Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials 55 Feb 09, 2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS) 56 Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences 57 Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy 57 Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease 58 Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 59 Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia 59 May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis 60 Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema 61 Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 61 Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma 62 Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer 63 Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference 64 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 65 Disclaimer 66
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16 Number of Products under Investigation by Universities/Institutes, H2 2017 17 Products under Investigation by Universities/Institutes, H2 2017 18 Number of Products by Stage and Mechanism of Actions, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 22 Number of Products by Stage and Molecule Type, H2 2017 24 Pipeline by AnGes MG Inc, H2 2017 25 Pipeline by F-star Biotechnology Ltd, H2 2017 26 Pipeline by Kringle Pharma Inc, H2 2017 26 Pipeline by M3 Biotechnology Inc, H2 2017 26 Pipeline by Minerva Biotechnologies Corp, H2 2017 27 Pipeline by Molecular Partners AG, H2 2017 27 Pipeline by ViroMed Co Ltd, H2 2017 28 Pipeline by Yooyoung Pharm Co Ltd, H2 2017 29 Dormant Products, H2 2017 51 Dormant Products, H2 2017 (Contd..1), H2 2017 52 Discontinued Products, H2 2017 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
